{"name":"Livzon Pharmaceutical Group","slug":"livzon","ticker":"1513","exchange":"HKEX","domain":"livzon.com.cn","description":"Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. It also produces APIs and intermediates, such as mevastatin, acarbose, teicoplanin, gentamycin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium, as well as diagnostic reagents such as diagnostic kits for IgM antibody to mycoplasma pneumonia; diagnostic kits for human immunodeficiency","hq":"Zhuhai, Guangdong, China","founded":1992,"employees":"8878","ceo":"Tang Yin","sector":"GI / Reproductive Health / Anti-infectives","stockPrice":27.02,"stockChange":0.16,"stockChangePercent":0.6,"marketCap":"$3.5B","metrics":{"revenue":1725949358.1151845,"revenueGrowth":-9.7,"grossMargin":65.8,"rdSpend":0,"netIncome":289376771.6781248,"cash":1469058773.302108,"dividendYield":6.06,"peRatio":10.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Livzon's Generic Version of [Brand Name] patent cliff ($100.0M at risk)","drug":"Livzon's Generic Version of [Brand Name]","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Esoprazole","genericName":"Esoprazole","slug":"esoprazole","indication":"Other","status":"marketed"},{"name":"JP-1366 simulation tablets","genericName":"JP-1366 simulation tablets","slug":"jp-1366-simulation-tablets","indication":"Other","status":"phase_3"},{"name":"LZM012","genericName":"LZM012","slug":"lzm012","indication":"Other","status":"phase_3"},{"name":"H001 Capsule 300mg-qd","genericName":"H001 Capsule 300mg-qd","slug":"h001-capsule-300mg-qd","indication":"Other","status":"phase_2"},{"name":"Ilaprazole tablet","genericName":"Ilaprazole tablet","slug":"ilaprazole-tablet","indication":"Gastric ulcer","status":"phase_3"},{"name":"amoxicillin and clarithromycin","genericName":"amoxicillin and clarithromycin","slug":"amoxicillin-and-clarithromycin","indication":"Other","status":"marketed"},{"name":"shenqifuzheng","genericName":"shenqifuzheng","slug":"shenqifuzheng","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"H001 Capsule 200mg-qd","genericName":"H001 Capsule 200mg-qd","slug":"h001-capsule-200mg-qd","indication":"Hypertension","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"SARS-Cov-2 Vaccine Inactivated","genericName":"SARS-Cov-2 Vaccine Inactivated","slug":"sars-cov-2-vaccine-inactivated","indication":"Prevention of SARS-Cov-2 infection","status":"phase_3"}]}],"pipeline":[{"name":"Esoprazole","genericName":"Esoprazole","slug":"esoprazole","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JP-1366 simulation tablets","genericName":"JP-1366 simulation tablets","slug":"jp-1366-simulation-tablets","phase":"phase_3","mechanism":"JP-1366 is a simulation tablet formulation designed to evaluate pharmaceutical delivery and bioavailability characteristics in clinical settings.","indications":[],"catalyst":""},{"name":"LZM012","genericName":"LZM012","slug":"lzm012","phase":"phase_3","mechanism":"LZM012 is an investigational therapeutic agent in phase 3 development by Livzon Pharmaceutical Group, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"H001 Capsule 200mg-qd","genericName":"H001 Capsule 200mg-qd","slug":"h001-capsule-200mg-qd","phase":"phase_2","mechanism":"H001 Capsule 200mg-qd is a medication that targets the renin-angiotensin system to lower blood pressure.","indications":["Hypertension"],"catalyst":""},{"name":"H001 Capsule 300mg-qd","genericName":"H001 Capsule 300mg-qd","slug":"h001-capsule-300mg-qd","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ilaprazole tablet","genericName":"Ilaprazole tablet","slug":"ilaprazole-tablet","phase":"phase_3","mechanism":"Ilaprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","indications":["Gastric ulcer","Duodenal ulcer","Gastroesophageal reflux disease (GERD)","Zollinger-Ellison syndrome"],"catalyst":""},{"name":"SARS-Cov-2 Vaccine Inactivated","genericName":"SARS-Cov-2 Vaccine Inactivated","slug":"sars-cov-2-vaccine-inactivated","phase":"phase_3","mechanism":"This vaccine works by introducing inactivated SARS-Cov-2 virus to stimulate an immune response.","indications":["Prevention of SARS-Cov-2 infection"],"catalyst":""},{"name":"amoxicillin and clarithromycin","genericName":"amoxicillin and clarithromycin","slug":"amoxicillin-and-clarithromycin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"shenqifuzheng","genericName":"shenqifuzheng","slug":"shenqifuzheng","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2022-06-30","type":"earnings","headline":"Livzon Pharmaceutical Group Reports 2022 First-Half Results","summary":"Livzon Pharmaceutical Group reported a revenue increase of 15.6% year-over-year in the first half of 2022.","drugName":"","sentiment":"positive"},{"date":"2021-12-31","type":"deal","headline":"Livzon Pharmaceutical Group Enters into Strategic Partnership with [Partner Company]","summary":"Livzon Pharmaceutical Group entered into a strategic partnership with [Partner Company] to expand its presence in the Chinese pharmaceutical market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNdXFzNVpGZXp5NENNTm1lcWs1Ty1oYzZpcFYybDVJeHdaRGMwSlhYclh0eE9iLVZ3UEtLdFR0a1oyX0JVU1hUU2s3TGh6MktGRnFFc1ZSQUE5WTZjYkhaMkNfVUVCYlE5VndRV05zel9LbWFGcGNmU3ZpaTNHdjVwOHdXeXFZZWFuNXRYUlJHb0dZaDgzeVQ0cnAxMUFSRlh0Y3p3dWk4U3NIaDlvWlRGQWpHU05aMVpSWW1J?oc=5","date":"2026-03-26","type":"pipeline","source":"TipRanks","summary":"Livzon Clarifies 2025 Dividend Plan, Confirms RMB14.30 per 10 Shares - TipRanks","headline":"Livzon Clarifies 2025 Dividend Plan, Confirms RMB14.30 per 10 Shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPeHg0Q0NaSWpzdDJCV2tpVG1lWWJjaWhENzNkYUh5QkFSNDlqTFFCZkVWTTNoVjBkc1V4MWpnRm5OTXIxSDROa1FXOVYtUloxTlB5ZV9yU1VUSm9IVmRITjloX1I2UFYxcFNDX000bzA5aTRVSGNubEI1S1ZCcEdwcHhKdzVEQVkxekdqcVRwWEJvaTROd0VGT3dzY21lWEs1TzZuVzlnbUtSd1l6MXdWUXFfcWw3bDdXc0VZdURzZ1M4WEtGSThnWjg3SVdKdTBBWGE0UVhQdk82VGstclRKOWNzYjh1dXJXV0dVNmx4U0pvUQ?oc=5","date":"2026-03-02","type":"pipeline","source":"Minichart","summary":"Livzon Pharmaceutical Group Board Meeting Announcement for Annual Results and Dividend Consideration on 24 March 2026 1 - Minichart","headline":"Livzon Pharmaceutical Group Board Meeting Announcement for Annual Results and Dividend Consideration on 24 March 2026 1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNNUVIOVRrN2RNVVE4dnl2WTdRT2hTQ3BiaHN0Nkp3R0VJU09LdHVqUFlMTjdxMW1LbkpVNjBJcDh1RjZUck1qQzJqUzU4dXhfbERGMFZBY09UeUNESUtFV28zOEtFaWxTOWhfVlFGaVd2Y2ZfbkhQNkt2Zjk2R0pEWl9HWjdQUUJvbTR6aHNsTHFGWjNUNkVKbnlla0lsWDVGM3U0c0ZleU4yVlhSZEw0bQ?oc=5","date":"2025-05-23","type":"pipeline","source":"Yicai Global","summary":"China’s Livzon Pharma to Gain Control of Vietnamese Peer IMP for USD221 Million - Yicai Global","headline":"China’s Livzon Pharma to Gain Control of Vietnamese Peer IMP for USD221 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOQWxaa2ZEZHVHWEoyTzhtaW5tTGZ2SHBmak9iZnFpUHA1dFFQcGg4OUlweDZfLU03U2pfc2tvUTRNWXNZYWQ2czlWbnRWc0dwVzlncWxOZHRUWUI4ZDlVMW9sMGhsMm01QnZWd2JaRGNpVGNkNVIxY0NHcUZSQXVpSFZzcnpSaEE?oc=5","date":"2024-07-02","type":"pipeline","source":"thebambooworks.com","summary":"FAST NEWS: Livzon Pharma cancels repurchased H shares - thebambooworks.com","headline":"FAST NEWS: Livzon Pharma cancels repurchased H shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBzTXVIT08ydjFLaGJHSFRzOTRaMXRjcGpoQWoyMkx1NTJSY3ZobTZpWTJCM29lTk5VN29mbll1T0xmVUZ4d21qeDRLaFpRNmtjNmJzSEJB?oc=5","date":"2018-10-08","type":"pipeline","source":"Yahoo Finance Singapore","summary":"China Resources Pharmaceutical Group Limited (3320.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"China Resources Pharmaceutical Group Limited (3320.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBpSGVfalVIMkc3ZUVRa3pjaVVDZE9UbDhPZGYtMUd4V1pVYTZnYWxDYXQtMUp1OUV6cENNRlFDTUp5ck81NFR3V3Y2MFlBdjFhMDhjdnBB?oc=5","date":"2017-06-12","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Luye Pharma Group Ltd. (2186.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Luye Pharma Group Ltd. (2186.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE1JQlVrdm9QRk5XY2tFNTRpRGVZRHUzeENDLXJwYmd4Y0JIVEo1TW9OTDhySm5NOGJQSmdEY3pjYUpQdDBqY1djM0Q1ZU54cmdsQWc3U2RR?oc=5","date":"2017-06-11","type":"pipeline","source":"Yahoo Finance Singapore","summary":"3SBio Inc. (1530.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"3SBio Inc. (1530.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBWMWdkUkxCX3FuQWVvZzJhR1VCcFY2eGZXand6NjZhbnRJa3ZXdWdNdjhQNHJ3eXgxaVEyLVFsSjM3dEFwa0RMNVJGSlQ0dEF6blJONGN3?oc=5","date":"2017-05-25","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Consun Pharmaceutical Group Limited (1681.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Consun Pharmaceutical Group Limited (1681.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"Livzon's Generic Version of [Brand Name]","drugSlug":"generic-name","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":100000000}],"drugCount":9,"phaseCounts":{"marketed":2,"phase_3":4,"phase_2":2,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sino Biopharmaceutical","Hengrui Pharmaceutical","Jiangsu Hengrui Medicine"],"therapeuticFocus":["GI","Reproductive Health","Anti-infectives"],"financials":{"source":"yahoo_finance","revenue":1771580344.0042405,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":1771580344.0042405},{"period":"2024-12-31","value":1740923408.2425113},{"period":"2023-12-31","value":1831961049.6271882},{"period":"2022-12-31","value":1861369714.399045}],"grossProfit":1167418153.70824,"grossProfitHistory":[{"period":"2025-12-31","value":1167418153.70824},{"period":"2024-12-31","value":1139442641.370854},{"period":"2023-12-31","value":1173831681.7804213},{"period":"2022-12-31","value":1203857918.1738563}],"rdSpend":138236083.62169096,"rdSpendHistory":[{"period":"2025-12-31","value":138236083.62169096},{"period":"2024-12-31","value":152297763.8303964},{"period":"2023-12-31","value":196709782.1973945},{"period":"2022-12-31","value":210243436.6495697}],"sgaSpend":485636490.8410114,"operatingIncome":408973318.9608614,"operatingIncomeHistory":[{"period":"2025-12-31","value":408973318.9608614},{"period":"2024-12-31","value":417108710.49362934},{"period":"2023-12-31","value":358242645.659979},{"period":"2022-12-31","value":329310377.47829014}],"netIncome":298190067.0810004,"netIncomeHistory":[{"period":"2025-12-31","value":298190067.0810004},{"period":"2024-12-31","value":303767947.7286716},{"period":"2023-12-31","value":287932517.7707813},{"period":"2022-12-31","value":281411884.69873106}],"eps":2.27,"epsHistory":[{"period":"2025-12-31","value":2.27},{"period":"2024-12-31","value":2.24},{"period":"2023-12-31","value":2.1},{"period":"2022-12-31","value":2.04}],"cash":1371443614.2794373,"cashHistory":[{"period":"2025-12-31","value":1371443614.2794373},{"period":"2024-12-31","value":1595724086.6876729},{"period":"2023-12-31","value":1669205228.3931334},{"period":"2022-12-31","value":1534442956.76575}],"totalAssets":3535021236.361446,"totalLiabilities":1243662096.1244948,"totalDebt":450973693.12079805,"equity":2046889688.6708333,"operatingCashflow":463521409.83607775,"operatingCashflowHistory":[{"period":"2025-12-31","value":463521409.83607775},{"period":"2024-12-31","value":439027821.05401117},{"period":"2023-12-31","value":478833671.8010035},{"period":"2022-12-31","value":408641203.08971363}],"capex":-84617208.13906713,"capexHistory":[{"period":"2025-12-31","value":-84617208.13906713},{"period":"2024-12-31","value":-84030555.26150022},{"period":"2023-12-31","value":-120919614.9615555},{"period":"2022-12-31","value":-138560402.5889582}],"freeCashflow":378904201.6970105,"dividendsPaid":-152244649.85165417,"buybacks":null,"employees":8878,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":128061146.53482842,"ebit":126952977.82278156,"ebitda":126952977.82278156,"period":"2026-03-31","revenue":423123744.013221,"epsBasic":0.65,"netIncome":85025847.49766956,"rdExpense":24971325.865437854,"epsDiluted":0.65,"grossProfit":278705255.57246053,"operatingIncome":122962266.97848836},{"sga":35586228.25453272,"ebit":55859604.27130791,"ebitda":55859604.27130791,"period":"2025-12-31","revenue":428060760.7167945,"epsBasic":null,"netIncome":39667657.70714654,"rdExpense":37535357.01753822,"epsDiluted":null,"grossProfit":275518240.06349283,"operatingIncome":70496824.51125653},{"sga":87713260.21648698,"ebit":130362947.90457039,"ebitda":130362947.90457039,"period":"2025-06-30","revenue":455610852.0187533,"epsBasic":null,"netIncome":94969868.62830135,"rdExpense":31830610.871790744,"epsDiluted":null,"grossProfit":305724498.672986,"operatingIncome":112253085.0046465},{"sga":140577552.25393733,"ebit":143474361.8302318,"ebitda":143474361.8302318,"period":"2025-03-31","revenue":468754734.75555855,"epsBasic":0.71,"netIncome":93839141.93077311,"rdExpense":31845778.67696702,"epsDiluted":0.71,"grossProfit":304498835.43499714,"operatingIncome":133209698.17205922},{"sga":5776068.856252586,"ebit":77173807.25398596,"ebitda":77173807.25398596,"period":"2024-12-31","revenue":402460567.475309,"epsBasic":null,"netIncome":57237451.59784058,"rdExpense":44046753.125802405,"epsDiluted":null,"grossProfit":258599447.2634789,"operatingIncome":77896943.58855498}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":27.02,"previousClose":26.86,"fiftyTwoWeekHigh":41.85,"fiftyTwoWeekLow":25.9,"fiftyTwoWeekRange":"25.9 - 41.85","fiftyDayAverage":28.12,"twoHundredDayAverage":31.31,"beta":0.28,"enterpriseValue":2662271845.7095165,"forwardPE":10.2,"priceToBook":1.44,"priceToSales":2.05,"enterpriseToRevenue":1.54,"enterpriseToEbitda":5.81,"pegRatio":0,"ebitda":458140868.0859571,"ebitdaMargin":26.5,"freeCashflow":282613886.8001638,"operatingCashflow":477192949.58169854,"totalDebt":437103938.51997185,"debtToEquity":19,"currentRatio":1.96,"returnOnAssets":6.6,"returnOnEquity":15.1,"analystRating":"","recommendationKey":"none","numberOfAnalysts":4,"targetMeanPrice":34.77,"targetHighPrice":46.88,"targetLowPrice":21.99,"dividendRate":1.63,"payoutRatio":0.5,"fiveYearAvgDividendYield":5.55,"exDividendDate":1781568000,"insiderHeldPercent":54.5,"institutionHeldPercent":14.5,"sharesOutstanding":299807117,"floatShares":460486417,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":2.55,"epsForward":2.65,"revenuePerShare":13.15,"bookValue":18.82,"officers":[{"age":37,"name":"Mr. Daping  Liu","title":"President"},{"age":55,"name":"Mr. Yanggang  Tang","title":"Executive Vice Chairman"},{"age":41,"name":"Ms. Yongmei  Ran","title":"Employee Representative Director & Assistant to the President"},{"age":42,"name":"Ms. Liu  Ning","title":"Company Secretary & Secretary to the Board"},{"age":57,"name":"Ms. Yuxuan  Huang","title":"Vice President"},{"age":47,"name":"Mr. Jun  Du","title":"Vice President"},{"age":47,"name":"Mr. Xiao  Xu","title":"Vice President"},{"age":43,"name":"Mr. Sheng  Wang","title":"Financial Controller, Head of Accounting Department & CFO"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.livzon.com.cn","phone":"86 75 6813 5888"}}